Novavax Inc NVAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVAX is a good fit for your portfolio.
News
-
Novavax Says It Can Deliver Recommended Covid Vaccine in September
-
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia
-
Novavax Shares Pop Another 50% Following Sanofi Deal
-
Novavax shares more than double on Sanofi's $1.4 billion investment for combo vaccine
-
Trending: Sanofi, Novavax to Develop New Covid-19 Vaccines
-
Novavax Shares Surge on $1.4 Billion Vaccine Licensing Deal with Sanofi
-
Novavax failed to capitalize on fears surrounding mRNA vaccines, activist investor says
-
Moderna Shares, Other Covid Vaccine Makers Hit by Warning From Pfizer
Trading Information
- Previous Close Price
- $279.10
- Day Range
- $250.00–274.00
- 52-Week Range
- $65.10–390.00
- Bid/Ask
- $257.60 / $279.00
- Market Cap
- $39.47 Bil
- Volume/Avg
- 6,592 / 7,318
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.22
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,992
- Website
- https://www.novavax.com
Comparables
Valuation
|
Metric
|
NVAX
|
002007
|
MRNA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 24.70 | 52.12 |
Price/Book Value | — | 2.69 | 4.18 |
Price/Sales | 2.22 | 5.94 | 10.50 |
Price/Cash Flow | — | 30.39 | — |
Price/Earnings
NVAX
002007
MRNA
Financial Strength
|
Metric
|
NVAX
|
002007
|
MRNA
|
|---|---|---|---|
Quick Ratio | 0.62 | 2.68 | 3.74 |
Current Ratio | 0.90 | 4.01 | 4.03 |
Interest Coverage | −26.84 | 140.38 | −148.54 |
Quick Ratio
NVAX
002007
MRNA
Profitability
|
Metric
|
NVAX
|
002007
|
MRNA
|
|---|---|---|---|
Return on Assets (Normalized) | −20.87% | 10.96% | −28.15% |
Return on Equity (Normalized) | — | 15.42% | −37.30% |
Return on Invested Capital (Normalized) | — | 12.13% | −36.39% |
Return on Assets
NVAX
002007
MRNA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Myvnnjc | Cmzpfgf | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tdkbvknxg | Khfzh | $114.2 Bil | |||
| Moderna Inc
MRNA
| Bhhjmtgw | Pttj | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Cbzgtqm | Qdfl | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Cjdbnfbkc | Zdr | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jcxjzvhh | Ljmzdl | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hdcddvyc | Hfhbp | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Zmkwccjy | Wlrkk | $12.8 Bil | |||
| Incyte Corp
INCY
| Gccccppdm | Fccfgk | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Sdflnlbgx | Nbrpk | $12.2 Bil |